TrialHuman vaccines & immunotherapeutics2022

A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses.

Gabriel I Nistor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.